Commercial

America’s Biopharmaceutical Companies Launch Groundbreaking, Multi-Year Initiative Heralding New Era of Medicine

January 24, 2017

PR Newswire, WASHINGTON, D.C. (January 23, 2017) The Pharmaceutical Research and Manufacturers of America (PhRMA) today launched a national, multi-year advertising and public affairs initiative on behalf of America’s biopharmaceutical companies. The campaign, GOBOLDLY, will showcase the industry’s unsung heroes driving cutting-edge advances in science and highlight the tremendous opportunity that exists to tackle our […]

Colorectal cancers market to approach $11 billion by 2025 as availability of branded therapies increases, says GlobalData

January 24, 2017

The colorectal cancer space, which covers the eight major markets (8MM) of the US, France, Germany, Italy, Spain, the UK, Japan, and China, is set to rise from $8.15 billion in 2015 to almost $11 billion by 2025, representing a moderate compound annual growth rate of 3%, according to research and consulting firm GlobalData. The […]

Antibacterial drugs market will hit $35.6 billion by 2022, as efforts increase to tackle antimicrobial resistance, says GBI Research

January 24, 2017

The antibacterial drugs market is set to grow from $27.7 billion in 2015 to $35.6 billion by 2022, representing a compound annual growth rate of 3.97%, according to business intelligence provider GBI Research. The company’s latest report states that emerging companies and the approvals of new products will drive this growth, along with the continued […]

Image Analysis Group Partners with Boston Medical Center/Boston University School of Medicine(BMC/BUSM)to Create Premiere Clinical Trials Management and Analytical Team

January 24, 2017

(London and Boston, January 17, 2017) Image Analysis Group(IAG)  announced today that they have partnered with a new CRO spun out by BMC/BUSM Radiology to provide life sciences, biotech, medical device and pharmaceutical clients with expert clinical research services in imaging. This partnership will offer IAG’s proprietary cloud-based platform Dynamika for clinical trial data management, […]

$420 Million Global Platelet Rich Plasma Market: Trend Analysis & Forecast to 2022 – Research and Markets

January 23, 2017

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Platelet Rich Plasma Market: Trend Analysis and Forecast to 2022” report to their offering. “Global Platelet Rich Plasma Market: Trend Analysis and Forecast to 2022” Tweet this The global platelet rich plasma market is projected to grow with a CAGR between 9.6% and 12% […]

Global Biosimilar Monoclonal Antibodies Market: Trend Analysis & Forecast to 2022 – Research and Markets

January 23, 2017

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Biosimilar Monoclonal Antibodies Market: Trend Analysis and Forecast to 2022” report to their offering. “Global Biosimilar Monoclonal Antibodies Market: Trend Analysis and Forecast to 2022” Tweet this The global biosimilar monoclonal antibodies market is projected to grow with a CAGR between 42.9% and 43.5% […]

HOST Therabiomics’ Investigational Compound, HOST-G904, Shown to Enhance Gut Microbiome Independent of Dietary Changes

January 23, 2017

Data validates microbiome as a potential treatment pathway for serious bowel conditions JERSEY, UNITED KINGDOM, January 17, 2017 – HOST Therabiomics, a microbiome-based therapeutics company, today announced positive results from a proof-of-concept trial for its investigational compound, HOST-G904. The study, published in the journal Alimentary Pharmacology & Therapeutics, demonstrated that HOST-G904 enriched the gastrointestinal (GI) […]

GDP – Time & Temperature Controlled Biopharma Pharma Logistics 6th Annual Brussels Cold Chain Conference

January 23, 2017

CSS 2017 (Cool Supply System & Solutions 2017) with 400+ has been in motion as an annual event for the past five years. Serving as a platform for premier Bio/Pharma Logistics providers involved in providing Services and Solutions within the Time & Temperature Controlled Logistics segment. 95% of the quality commitment is focused on new […]

IMBRUVICA® (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy

January 20, 2017

HORSHAM, Pa., Jan. 19, 2017 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.1 Accelerated approval was granted for this indication based on overall response rate (ORR). Continued […]

Allergan Announces FDA Approval Of RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For The Topical Treatment Of Persistent Facial Erythema Associated With Rosacea In Adults

January 20, 2017

DUBLIN, Jan. 19, 2017 /PRNewswire/ — Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today the approval of RHOFADE™ cream by the U.S. Food and Drug Administration (FDA) for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary […]

Synergy Pharmaceuticals’ TRULANCE™ (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation

January 20, 2017

NEW YORK–(BUSINESS WIRE)–Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the U.S. Food and Drug Administration (FDA) has approved TRULANCE™ (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC). TRULANCE is the first drug designed to replicate the function of uroguanylin, a naturally occurring and endogenous human gastrointestinal (GI) peptide that is thought to […]

Hovione and LEWA Bio Process Technologies to Drive Continuous Processing in Pharma

January 20, 2017

06 Jan 2017, Boston, USA – Hovione and LEWA Bio Process Technologies confirmed as sponsors at Commercializing Continuous Processing in Pharma (Jan 30 – Feb 1, 2017) in Boston. Following the two successful commercial continuous manufacturing approvals by the FDA last April (Vertex and Johnson & Johnson), pharma and biotech companies are all eyeing up […]

GlaxoSmithKline sponsors MIT real-world data flu app in the hope it goes viral

January 19, 2017

GSK is sponsoring a new Android mobile app that was created with the aim to raise awareness, educate users and collect health outcomes data relating to the flu and other ailments. The app, Flumoji, was developed by MIT Connection Science, a cross-discipline group from the US Institute, and is being positioned as a ‘health wizard’. […]

Meet Forward, An Ex-Googler’s Plan To Reinvent Health Care With A Dose Of Apple, Netflix And AI

January 19, 2017

Last week, the windows of Forward, a new health care startup on a busy corner of San Francisco’s Financial District, were covered with eye-catching images: bold blue slashes from the company’s logo, exhortations to “move forward with your health,” and an outline of female and male bodies showing lungs and heart linked to a monitoring […]

Mastercard and Gilead Pilot Program For Digitized Healthcare

January 19, 2017

PURCHASE, N.Y. – January 18, 2017 – Mastercard has signed a Memorandum of Understanding (MoU) with Gilead Sciences, Inc. to explore the potential use of the Mastercard Aid Network to simplify the delivery of hepatitis C treatment in a resource limited setting with high disease burden. MasterCard_Aid_Network[1][2][3] The Mastercard Aid Network is a non-financial digital […]

Harris Poll: Only Nine Percent of U.S. Consumers Believe Pharma and Biotechnology Put Patients over Profits

January 19, 2017

NEW YORK – Only nine percent of U.S. consumers believe pharmaceutical and biotechnology companies put patients over profits, while only 16 percent believe health insurance companies do, according to a Harris Poll study released today. Meanwhile, 36 percent of U.S. adults believe health care providers (such as doctors and nurses) put patients over profits, compared […]

Joanna Engelke Joins Halloran Consulting Group as Managing Director

January 19, 2017

Former Senior Vice President, Global Quality & Regulatory at Boston Scientific Brings Quality Expertise to Halloran   BOSTON – Halloran Consulting Group, a national consultancy to life science companies of all sizes, today announced that Joanna Engelke has joined the company as managing director and will work to guide Halloran clients around complex regulatory and quality […]

New First-of-Its-Kind Study Shows Growing Share of Medicine List Prices Going to Rebates and Supply Chain

January 19, 2017

WASHINGTON, Jan. 18, 2017 /PRNewswire-USNewswire/ — Robust competition in the private marketplace is resulting in increasingly higher rebates and discounts on medicine prices, according to a new study by the Berkeley Research Group (BRG). The study is among the first to examine the share of prescription medicine spending retained by biopharmaceutical companies, generic manufacturers, pharmacy […]

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) – a Rare Type of Non-Hodgkin’s Lymphoma

January 19, 2017

NORTH CHICAGO, Ill., Jan. 19, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.1 This indication is […]

IMBRUVICA® (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy First therapy specifically indicated for this rare blood cancer; represents fifth indication for IMBRUVICA in the U.S.

January 19, 2017

HORSHAM, Pa., Jan. 19, 2017 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.1 Accelerated approval was granted for this indication based on overall response rate (ORR). Continued […]

FEEDBACK